Evaluation of the rubidium efflux assay for preclinical identification of HERG blockade.

Inhibition of the delayed-rectifier potassium channel current, human ether-a-go-go (hERG), by pharmaceutical agents can lead to acquired long QT syndrome and the generation of potentially lethal arrhythmias and sudden death. There remains an unmet need for higher-throughput assays to screen compounds in preclinical development for the potential to block hERG and cause QT prolongation. We evaluated the rubidium efflux assay for its ability to determine block of the hERG potassium channel. hERG-transfected human embryonic kidney-293 cells were cultured on 96-well assay plates and loaded with rubidium ion by incubating in media in which potassium was replaced by 5.4 mM Rb+. Cells were exposed to test compounds and then depolarized with a K+ channel opening buffer containing 50 mM K+. The supernatant was removed, and cells were lysed using 0.1% Triton X-100. Concentration-response curves were generated for test agents by determining the Rb+ efflux using a flame atomic absorption spectrometer. Multiple trials with cisapride yielded 50% inhibitory concentration values between 308.1 +/- 11 nM to 456.3 +/- 24 nM for inhibition of Rb+ efflux and a Z factor of 0.80 +/- 0.07 (n = 5 plates, 12 wells per plate). The values for inhibition of the hERG channel exhibited a rightward shift in potency as compared to those measured using electrophysiological techniques. In addition, we evaluated 19 blinded compounds at 10 microM in the Rb+ efflux assay, and compared results to those using patch clamp electrophysiology and the dofetilide displacement binding assay. The dofetilide displacement binding assay yielded a good correlation with electrophysiological measurements of hERG block. The rubidium efflux assay lacked sensitivity to consistently identify significant channel blockade. In conclusion, the rubidium efflux assay provides a higher-throughput means to identify potent hERG channel blocking agents, but lacks the sensitivity required to accurately determine the potency of blockade.

[1]  Rita R. Patel,et al.  A High-Throughput HERG Potassium Channel Function Assay: An Old Assay with a New Look , 2002, Drug development and industrial pharmacy.

[2]  T. Garyantes,et al.  Development and Evaluation of High Throughput Functional Assay Methods for hERG Potassium Channel , 2001, Journal of biomolecular screening.

[3]  J. Sullivan,et al.  Potassium channels: molecular defects, diseases, and therapeutic opportunities. , 2000, Pharmacological reviews.

[4]  A. Brown,et al.  Drugs, hERG and sudden death. , 2004, Cell calcium.

[5]  A. Brown,et al.  Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. , 2004, Journal of pharmacological and toxicological methods.

[6]  N. Carruthers,et al.  Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. , 2005, Journal of medicinal chemistry.

[7]  J. Warmke,et al.  A family of potassium channel genes related to eag in Drosophila and mammals. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Sanguinetti,et al.  Long QT Syndrome: , 2000, Journal of cardiovascular electrophysiology.

[9]  F. Lang,et al.  Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole , 1996, FEBS letters.

[10]  M. Sanguinetti,et al.  Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents , 1990, The Journal of general physiology.

[11]  R. Felix Channelopathies: ion channel defects linked to heritable clinical disorders , 2000, Journal of medical genetics.

[12]  U. Littauer,et al.  Sodium-dependent efflux of K+ and Rb+ through the activated sodium channel of neuroblastoma cells. , 1976, Biochemical and biophysical research communications.

[13]  A. Grant,et al.  Emerging Class III Antiarrhythmic Agents:Mechanism of Action and Proarrhythmic Potential , 1997, Cardiovascular Drugs and Therapy.

[14]  Stanley Nattel,et al.  Dofetilide block involves interactions with open and inactivated states of HERG channels , 2002, Pflügers Archiv - European Journal of Physiology.

[15]  Gregory W. Kauffman,et al.  Physicochemical Features of the hERG Channel Drug Binding Site* , 2004, Journal of Biological Chemistry.

[16]  M. Sanguinetti,et al.  Lanthanum blocks a specific component of IK and screens membrane surface change in cardiac cells. , 1990, The American journal of physiology.

[17]  G. Robertson,et al.  HERG, a human inward rectifier in the voltage-gated potassium channel family. , 1995, Science.

[18]  Michael C Sanguinetti,et al.  Molecular Determinants of Voltage-dependent Human Ether-a-Go-Go Related Gene (HERG) K+ Channel Block* , 2002, The Journal of Biological Chemistry.

[19]  W. Crumb,et al.  Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. , 2004, Journal of pharmacological sciences.

[20]  Soo Sen Lee,et al.  Flux assays in high throughput screening of ion channels in drug discovery. , 2003, Assay and drug development technologies.

[21]  S. Miller A rapid bioassay method for gramicidin by measuring rubidium ion leakage from Streptococcus faecalis. , 1979, The Journal of applied bacteriology.

[22]  M. Sanguinetti,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Browna Drugs , hERG and sudden death , 2004 .

[24]  A. Shrier,et al.  Potassium channel blockade: A mechanism for suppressing ventricular fibrillation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Fedida,et al.  Rb+ Flux through hERG Channels Affects the Potency of Channel Blocking Drugs: Correlation with Data Obtained Using a High-Throughput Rb+ Efflux Assay , 2004, Journal of biomolecular screening.

[26]  M. Sanguinetti,et al.  Molecular Basis for Kv1.5 Channel Block , 2004, Journal of Biological Chemistry.

[27]  F. Ponti,et al.  QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience , 2000, European Journal of Clinical Pharmacology.

[28]  C. January,et al.  Block of HERG Potassium Channels by the Antihistamine Astemizole and its Metabolites Desmethylastemizole and Norastemizole , 1999, Journal of cardiovascular electrophysiology.

[29]  Andreas Ebneth,et al.  HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery. , 2003, Current opinion in drug discovery & development.

[30]  G. Terstappen,et al.  Functional analysis of native and recombinant ion channels using a high-capacity nonradioactive rubidium efflux assay. , 1999, Analytical biochemistry.

[31]  Jiesheng Kang,et al.  A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. , 2002, European journal of pharmacology.

[32]  Gary A Gintant,et al.  The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o. , 2004, Journal of pharmacological and toxicological methods.

[33]  Fred J. Sigworth,et al.  Structural biology: Life's transistors , 2003, Nature.

[34]  A. Brown,et al.  A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG , 1997, FEBS letters.

[35]  C. January,et al.  Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. , 1998, Molecular pharmacology.

[36]  T. Priestley,et al.  Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen. , 2005, Assay and drug development technologies.

[37]  O. Pongs,et al.  Screening lead compounds for QT interval prolongation. , 2001, Drug discovery today.

[38]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[39]  R. Hamid,et al.  Comparison of alamar blue and MTT assays for high through-put screening. , 2004, Toxicology in vitro : an international journal published in association with BIBRA.

[40]  D. Wysowski,et al.  Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions , 2001, American Journal of Gastroenterology.

[41]  Maurizio Recanatini,et al.  Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes , 2002, Drug safety.

[42]  D. Snyders,et al.  High affinity open channel block by dofetilide of HERG expressed in a human cell line. , 1996, Molecular pharmacology.

[43]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[44]  R. H. Steinberg,et al.  Potassium transport across the frog retinal pigment epithelium , 2005, The Journal of Membrane Biology.

[45]  M. Cadene,et al.  X-ray structure of a voltage-dependent K+ channel , 2003, Nature.

[46]  R. H. Steinberg,et al.  Potassium modulation of taurine transport across the frog retinal pigment epithelium , 1979, The Journal of general physiology.

[47]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[48]  T J Campbell,et al.  Inhibition of the human ether‐a‐go‐go‐related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states , 1999, British journal of pharmacology.

[49]  M. D. Suárez,et al.  Mevalonate phosphorylation in the neonatal chick liver. , 1976, Biochemical and biophysical research communications.